Loncastuximab tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma
Positive results from the pivotal 145-patient phase 2 clinical trial of Loncastuximab tesirine ( ADCT-402 ) for the treatment of relapsed or refractory diffuse large B-cell lymphoma ( DLBCL )
were an ...
read article